Document is current

Article History

Received: 2 June 2025

Accepted: 26 November 2025

First Online: 25 January 2026

Declarations

:

: The research was granted an exemption by WCG IRB (Puyallup, WA) under exemption category 45 CFR 46.104(d)(4) for secondary research involving minimal risk to individuals. All data were analyzed in compliance with institutional and federal regulations.

: Not applicable.

: MDL has served as a consultant for BioCryst, CSL, Intellia, Pharming, and Takeda, has received research support from Intellia, and has provided speaker presentations for AstraZeneca, BioCryst, CSL, Intellia, Pharming, and Takeda. RT has served as a consultant or received research support from Astria, BioCryst, CSL Behring, Ionis, KalVista, Pharming, Pharvaris, and Takeda and has provided speaker presentations for BioCryst, CSL Behring, Pharming, and Takeda. LLG was an employee of BioCryst Pharmaceuticals, Inc. at the time of the study. PG, ML, and SNP are employees of and own stock/stock options in BioCryst Pharmaceuticals, Inc. SDM and FL are employees of Groupe d’analyse SRI, a consulting company that has provided paid consulting services to BioCryst Pharmaceuticals, Inc., which funded the development and conduct of this study and manuscript. RR is an employee of Analysis Group, Inc., a consulting company that has provided paid consulting services to BioCryst Pharmaceutical, Inc., which funded the development and conduct of this study and manuscript. WRL has received research grants from Astria, CSL Behring, Ionis, KalVista, and Pharvaris, consultancy fees from Astria, BioCryst, CSL Behring, Intellia, KalVista, Pharming, Pharvaris, and Takeda, payment or honoraria from BioCryst, CSL Behring, Pharming, and Takeda, participated on advisory boards for Astria, BioCryst, CSL Behring, Intellia, KalVista, Pharming, Pharvaris, and Takeda, and is a member of the Medical Advisory Board for US Hereditary Angioedema Association (HAEA).